ASHM administers the Hepatitis B Community s100 Prescriber Program in all states and territories of Australia (in Victoria as a partner in the VHHITAL program). The program provides initial training, ongoing support and continuing professional development (CPD) activities for general practitioners to enable them to prescribe Highly Specialised Drugs (HSD) for the treatment of chronic hepatitis B. See http://www.ashm.org.au/HBV/prescriber-programs/ for further information.

The purpose of this evaluation is to:

·         Measure the impact of the implementation of the program and the extent to which the expected outcomes were achieved

·         Facilitate continuous quality improvement by outlining the successes of the program as well as opportunities for change

·         Provide recommendations to further optimise the program to achieve its outcomes

Scope

The evaluation will:

·         Assess the delivery of the program, and factors enabling or impacting successful delivery

·         Assess the quality and relevance of program activities to GPs

·         Assess the extent to which the program outcomes have been achieved

·         Provide an estimate of the value of the program to the health care system per patient involved

·         Comprehensively identify changes to practice which have occurred as a result of participation in the program

·         Identify further support systems to facilitate a community of practice among GPs managing CHB

·         Identify clear improvements and recommendations to be implemented within or alongside the program in the future

 

The evaluation must examine both regional and metropolitan prescribers across all states and territories. The time period for evaluation is 1 July 2015 to 31 December 2017.

 

To download full details of the Request for Expressions of Interest - PLEASE CLICK HERE

 

Expressions of interest close 1 December 2017.